Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

She recommends women undergo a “baseline” dual-energy X-ray absorptiometry (DEXA) scan in their early to mid-30s to help ...

Chinese drugmaker Guangzhou Innogen Pharmaceutical had a strong debut in Hong Kong, cashing in on positive sentiment toward its flagship drug and Chinese biotech stocks in general.

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

Tiny "hidden" proteins lurking in DNA once dismissed as junk may hold the key to the next generation of obesity drugs, ...

Current weight-loss and diabetes medications, such as GLP-1 drugs, often fail to deliver lasting results and are plagued by ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ ...